Abstract
Background: A hallmark of atherosclerosis is its complex pathogenesis, which is dependent on altered cholesterol metabolism and inflammation. Both arms of pathogenesis involve myeloid cells. Monocytes migrating into the arterial walls interact with modified low-density lipoprotein (LDL) particles, accumulate cholesterol and convert into foam cells, which promote plaque formation and also contribute to inflammation by producing proinflammatory cytokines. A number of studies characterized transcriptomics of macrophages following interaction with modified LDL, and revealed alteration of the expression of genes responsible for inflammatory response and cholesterol metabolism. However, it is still unclear how these two processes are related to each other to contribute to atherosclerotic lesion formation.
Methods: We attempted to identify the main mater regulator genes in macrophages treated with atherogenic modified LDL using a bioinformatics approach.
Results: We found that most of the identified genes were involved in inflammation, and none of them was implicated in cholesterol metabolism. Among the key identified genes were interleukin (IL)-7, IL-7 receptor, IL- 15 and CXCL8.
Conclusion: Our results indicate that activation of the inflammatory pathway is the primary response of the immune cells to modified LDL, while the lipid metabolism genes may be a secondary response triggered by inflammatory signalling.
Keywords: Atherosclerosis, inflammation, macrophages, LDL, modified LDL, pro-inflammatory signaling.
Current Pharmaceutical Design
Title:Modified LDL Particles Activate Inflammatory Pathways in Monocyte-derived Macrophages: Transcriptome Analysis
Volume: 24 Issue: 26
Author(s): Alexander N. Orekhov*, Yumiko Oishi , Nikita G. Nikiforov, Andrey V. Zhelankin, Larisa Dubrovsky, Igor A. Sobenin, Alexander Kel, Daria Stelmashenko, Vsevolod J. Makeev, Kathy Foxx, Xueting Jin, Howard S. Kruth and Michael Bukrinsky
Affiliation:
- Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow,Russian Federation
Keywords: Atherosclerosis, inflammation, macrophages, LDL, modified LDL, pro-inflammatory signaling.
Abstract: Background: A hallmark of atherosclerosis is its complex pathogenesis, which is dependent on altered cholesterol metabolism and inflammation. Both arms of pathogenesis involve myeloid cells. Monocytes migrating into the arterial walls interact with modified low-density lipoprotein (LDL) particles, accumulate cholesterol and convert into foam cells, which promote plaque formation and also contribute to inflammation by producing proinflammatory cytokines. A number of studies characterized transcriptomics of macrophages following interaction with modified LDL, and revealed alteration of the expression of genes responsible for inflammatory response and cholesterol metabolism. However, it is still unclear how these two processes are related to each other to contribute to atherosclerotic lesion formation.
Methods: We attempted to identify the main mater regulator genes in macrophages treated with atherogenic modified LDL using a bioinformatics approach.
Results: We found that most of the identified genes were involved in inflammation, and none of them was implicated in cholesterol metabolism. Among the key identified genes were interleukin (IL)-7, IL-7 receptor, IL- 15 and CXCL8.
Conclusion: Our results indicate that activation of the inflammatory pathway is the primary response of the immune cells to modified LDL, while the lipid metabolism genes may be a secondary response triggered by inflammatory signalling.
Export Options
About this article
Cite this article as:
Orekhov N. Alexander *, Oishi Yumiko , Nikiforov G. Nikita , Zhelankin V. Andrey , Dubrovsky Larisa , Sobenin A. Igor , Kel Alexander, Stelmashenko Daria , Makeev J. Vsevolod , Foxx Kathy , Jin Xueting , Kruth S. Howard and Bukrinsky Michael , Modified LDL Particles Activate Inflammatory Pathways in Monocyte-derived Macrophages: Transcriptome Analysis, Current Pharmaceutical Design 2018; 24 (26) . https://dx.doi.org/10.2174/1381612824666180911120039
DOI https://dx.doi.org/10.2174/1381612824666180911120039 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Pharmacologic Strategies to Protect the Liver from Ischemia- Reperfusion Injury
Recent Patents on Cardiovascular Drug Discovery Involvement of Cytokines and Inflammation in Catecholamine-Induced Pulmonary Injury in Rats
Vascular Disease Prevention (Discontinued) A Study of Extrapyramidal Manifestations Accompanying Decompensated Viral Hepatic Cirrhosis Patients
Reviews on Recent Clinical Trials A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Effect of Stigmas of Crocus sativus L. (saffron) on Cell Mediated and Humoral Immunity
The Natural Products Journal Recent Insights into the Role of Prostanoids in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
Current Clinical Pharmacology (Commentary [Research Highlights] A Toll Road to Alzheimer Disease?)
CNS & Neurological Disorders - Drug Targets Reported Dose as a Measure of Drug Exposure after Paracetamol Overdose in Children
Current Clinical Pharmacology Bacterial Adaptation and Infection
Inflammation & Allergy - Drug Targets (Discontinued) Mass Spectrometry Characterization of Plant Phosphoproteins
Current Protein & Peptide Science Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation
Current Pharmaceutical Design Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
Current Neuropharmacology Behavioral Experimental Paradigms for the Evaluation of Drug’s Influence on Cognitive Functions: Interpretation of Associative, Spatial/Nonspatial and Working Memory
CNS & Neurological Disorders - Drug Targets Dysregulated Interleukin -33/ST2 Pathway Perpetuates Chronic Inflammation in Hashimoto’s Thyroiditis
Endocrine, Metabolic & Immune Disorders - Drug Targets Parthenogenetic Cell Lines: An Unstable Equilibrium Between Pluripotency and Malignant Transformation
Current Pharmaceutical Biotechnology Biology of Heme: Drug Interactions and Adverse Drug Reactions with CYP450
Current Topics in Medicinal Chemistry CoMFA and CoMSIA Analyses of Highly Selective Pipecolic Acid Based TNF-α Converting Enzyme (TACE) Inhibitors Using Docked Conformations for Molecular Alignment
Letters in Drug Design & Discovery